Loading clinical trials...
Loading clinical trials...
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3461767 in Healthy Participants
Conditions
Interventions
LY3461767 - SC
LY3461767 - IV
+1 more
Locations
3
United States
Covance Clinical Research Inc
Daytona Beach, Florida, United States
Covance Dallas
Dallas, Texas, United States
Lilly Nus Centre for Clin Pharmacology
Singapore, Singapore
Start Date
June 15, 2020
Primary Completion Date
January 13, 2021
Completion Date
January 13, 2021
Last Updated
February 5, 2021
NCT00090662
NCT06290258
NCT07310264
NCT06716502
NCT07483606
NCT06342713
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions